BR112014020271A8 - PHARMACEUTICAL COMPOSITION AND METHODS TO DECREASE URINATION FREQUENCY IN PATIENTS - Google Patents

PHARMACEUTICAL COMPOSITION AND METHODS TO DECREASE URINATION FREQUENCY IN PATIENTS

Info

Publication number
BR112014020271A8
BR112014020271A8 BR112014020271A BR112014020271A BR112014020271A8 BR 112014020271 A8 BR112014020271 A8 BR 112014020271A8 BR 112014020271 A BR112014020271 A BR 112014020271A BR 112014020271 A BR112014020271 A BR 112014020271A BR 112014020271 A8 BR112014020271 A8 BR 112014020271A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
methods
decrease
patients
patient
Prior art date
Application number
BR112014020271A
Other languages
Portuguese (pt)
Other versions
BR112014020271A2 (en
Inventor
A Dill David
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of BR112014020271A2 publication Critical patent/BR112014020271A2/pt
Publication of BR112014020271A8 publication Critical patent/BR112014020271A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA E MÉTODOS PARA DIMINUIR A FREQUÊNCIA DE MICÇÃO EM PACIENTE. São revelados métodos e composições para diminuir a frequência de micção. Um método compreende administrar a um paciente que dela necessite uma quantidade efetiva de uma composição farmacêutica que compreende um agente analgésico formulado para a liberação prolongada. Outro método compreende administrar a um paciente que dela necessite uma quantidade efetiva de uma composição farmacêutica que compreende vários ingredientes ativos formulados para a liberação prolongada.PHARMACEUTICAL COMPOSITION AND METHODS TO DECREASE URINATION FREQUENCY IN A PATIENT. Methods and compositions for decreasing the frequency of urination are disclosed. One method comprises administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated for sustained release. Another method comprises administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising various active ingredients formulated for sustained release.

BR112014020271A 2012-03-19 2013-03-13 PHARMACEUTICAL COMPOSITION AND METHODS TO DECREASE URINATION FREQUENCY IN PATIENTS BR112014020271A8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2013/030901 WO2013142197A1 (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (2)

Publication Number Publication Date
BR112014020271A2 BR112014020271A2 (en) 2017-06-20
BR112014020271A8 true BR112014020271A8 (en) 2017-07-11

Family

ID=49223209

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014020271A BR112014020271A8 (en) 2012-03-19 2013-03-13 PHARMACEUTICAL COMPOSITION AND METHODS TO DECREASE URINATION FREQUENCY IN PATIENTS
BR112014020113A BR112014020113A8 (en) 2012-03-19 2013-03-14 PHARMACEUTICAL COMPOSITIONS AND METHOD TO DECREASE URINATION FREQUENCY

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112014020113A BR112014020113A8 (en) 2012-03-19 2013-03-14 PHARMACEUTICAL COMPOSITIONS AND METHOD TO DECREASE URINATION FREQUENCY

Country Status (15)

Country Link
EP (2) EP2827852A4 (en)
JP (5) JP2015510928A (en)
KR (4) KR20140134333A (en)
CN (4) CN104302284A (en)
AU (4) AU2013235518B2 (en)
BR (2) BR112014020271A8 (en)
CA (2) CA2866853A1 (en)
HK (3) HK1204553A1 (en)
MX (3) MX2014011128A (en)
MY (2) MY174090A (en)
NZ (6) NZ630471A (en)
RU (3) RU2669565C2 (en)
SG (2) SG11201500408VA (en)
WO (2) WO2013142197A1 (en)
ZA (2) ZA201405862B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
ES2910361T3 (en) 2013-07-23 2022-05-12 Serenity Pharmaceuticals Llc Compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
JP2017516832A (en) * 2014-06-06 2017-06-22 ウェルズリー ファーマスーティカルズ、エルエルシー Pharmaceutical formulations for reducing urination frequency and methods of use thereof
KR101809908B1 (en) 2014-07-21 2018-01-25 주식회사 종근당 Pharmaceutical composition comprising 5-α reductase inhibitor
AU2015349811B2 (en) * 2014-11-20 2021-05-06 Acerus Pharmaceuticals USA, LLC Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
JP2018529710A (en) * 2015-09-30 2018-10-11 ウェルズリー ファーマスーティカルズ、エルエルシー Composition for reducing the frequency of urination, and methods of making and using the same
CN105238124B (en) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 A kind of antibacterial mastic powder
JP6294924B2 (en) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ Vehicle travel control device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2320193A1 (en) * 1998-02-10 1999-08-19 Welfide Corporation Controlled release preparation
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (en) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa opiate agonists for the treatment of diseases of the bladder
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CN1633283A (en) * 2002-02-19 2005-06-29 法玛西雅公司 Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
US20060035923A1 (en) * 2002-06-07 2006-02-16 Rian Van Meeteren Overactive bladder treating drug
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
DE602004003172T2 (en) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham METHOD FOR THE TREATMENT OF DISEASES OF THE LOWER HARN PATHS WITH ANTIMIC CARCINICS AND WITH MODULATORS OF THE ALPHA-2-DELTA SUB-UNIT OF THE CALCIUM CHANNEL
BR0318201A (en) * 2003-03-21 2006-03-21 Mcneil Ppc Inc non-steroidal anti-inflammatory drug dosage regimen
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
US8685924B2 (en) * 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
KR20080043763A (en) * 2005-06-17 2008-05-19 다이나미스 테라퓨틱스, 인코포레이티드 Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
JP5312027B2 (en) * 2005-09-02 2013-10-09 セラヴィダ、インク Disease treatment
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Also Published As

Publication number Publication date
AU2013235518A2 (en) 2014-10-09
NZ718163A (en) 2017-09-29
KR20190003840A (en) 2019-01-09
AU2013235507A1 (en) 2014-08-21
BR112014020113A2 (en) 2017-06-20
JP2018024693A (en) 2018-02-15
MY174090A (en) 2020-03-09
RU2014142066A (en) 2016-05-10
JP2015510936A (en) 2015-04-13
NZ628079A (en) 2016-05-27
ZA201406146B (en) 2016-08-31
RU2014142025A (en) 2016-05-10
NZ714288A (en) 2016-12-23
SG11201500408VA (en) 2015-03-30
RU2669565C2 (en) 2018-10-12
WO2013142197A1 (en) 2013-09-26
EP2827852A1 (en) 2015-01-28
MX2014011128A (en) 2015-08-10
EP2827852A4 (en) 2016-03-02
ZA201405862B (en) 2016-08-31
AU2017203139A1 (en) 2017-06-01
RU2599017C2 (en) 2016-10-10
NZ714662A (en) 2016-08-26
WO2013142274A1 (en) 2013-09-26
RU2016133305A (en) 2018-12-10
SG11201500409SA (en) 2015-03-30
AU2013235518B2 (en) 2017-03-02
CA2866755A1 (en) 2013-09-26
CN107157991A (en) 2017-09-15
MX2019008817A (en) 2019-09-26
AU2017203139B2 (en) 2018-07-19
KR20140134333A (en) 2014-11-21
HK1251469A1 (en) 2019-02-01
KR20170015537A (en) 2017-02-08
HK1243921A1 (en) 2018-07-27
KR20140134284A (en) 2014-11-21
CN104321056A (en) 2015-01-28
BR112014020113A8 (en) 2017-07-11
JP2015510928A (en) 2015-04-13
JP2018138602A (en) 2018-09-06
AU2017203246B2 (en) 2018-10-18
EP2827851A1 (en) 2015-01-28
AU2017203246A1 (en) 2017-06-08
AU2013235518A1 (en) 2014-09-25
HK1204553A1 (en) 2015-11-27
CN107789626A (en) 2018-03-13
MX2014011129A (en) 2015-08-10
CN104302284A (en) 2015-01-21
MY175764A (en) 2020-07-08
BR112014020271A2 (en) 2017-06-20
CA2866853A1 (en) 2013-07-26
RU2016133305A3 (en) 2018-12-10
EP2827851A4 (en) 2015-10-14
AU2013235507B2 (en) 2017-03-23
JP2016172752A (en) 2016-09-29
NZ712594A (en) 2016-09-30
NZ630471A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
BR112014020271A8 (en) PHARMACEUTICAL COMPOSITION AND METHODS TO DECREASE URINATION FREQUENCY IN PATIENTS
CY1120888T1 (en) TRANSPARENT PHARMACEUTICAL COMPOSITIONS INCLUDING ACTIVE AGENTS
BR112014016550A2 (en) delayed release formulation to reduce urination frequency and method of use
MX2011008448A (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia.
BR112012023021A2 (en) indazole compounds and their uses
BR112013002601A2 (en) corticosteroids for joint pain treatment
AR084932A1 (en) OPHTHALMIC COMPOSITION INCLUDING AN ANDROGEN AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF AN EYE DISEASE RESULTING FROM AN ANDROGENIC DEFICIENCY
UY32919A (en) Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses
BR112014016661A2 (en) prolonged release formulation to reduce urination frequency and method of use
BR112013008601A8 (en) CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS
MY173215A (en) Acetylcysteine compositions and methods of use thereof
BR112016001446A8 (en) therapeutic compositions, combination product, in vitro use of flecainide and flecainide
PE20140255A1 (en) DISPERSIBLE TABLET IN ORAL FORM
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
UY33530A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES
BR112015001627A2 (en) pharmaceutical composition, their uses and method of decreasing the frequency of urination
UA112418C2 (en) THERAPEUTIC DISEASE
UY34080A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES FEXOFENADINE AND PREPARATION METHODS
CO6602160A2 (en) Oral b12 therapy
NI201200196A (en) THERAPEUTIC AGENTS 976
DOP2015000127A (en) PHARMACEUTICAL FORMULATION OF N- [5- [2- (3,5-DIMETOXIFENIL) ETIL] -2H-PIRAZOL-3-IL] -4 - [(3R, 5S) -3,5-DIMETHYLIPIPERAZIN-1-IL] BENZAMIDA
ECSP12012332A (en) ASSOCIATION OF INHIBITORS OF XANTINA OXIDASE AND THE INSTATINE AND ITS USE
ES2422563A1 (en) Injectable pharmaceutical composition of ibuprofen and arginine, its preparation procedure, unit dosage form and use thereof (Machine-translation by Google Translate, not legally binding)
UA111785C2 (en) A COMPOSITION FOR THE TREATMENT OF Warts And A WAY OF TREATMENT
CO6630144A2 (en) Association of xanthine oxidase and instatin inhibitors and their use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements